Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer
Autor: | Stephanie L. Hines, Sarah K. Macklin-Mantia, Pashtoon Murtaza Kasi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Genetic testing lcsh:QH426-470 PALB2 030105 genetics & heredity lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine BRCA1/2 Internal medicine Pancreatic cancer medicine PARP inhibitors Genetics (clinical) Predictive marker medicine.diagnostic_test business.industry Medical record Research Cancer medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Hereditary cancer Platinum chemotherapy lcsh:Genetics medicine.anatomical_structure 030220 oncology & carcinogenesis Medical genetics Pancreas business |
Zdroj: | Hereditary Cancer in Clinical Practice Hereditary Cancer in Clinical Practice, Vol 18, Iss 1, Pp 1-5 (2020) |
ISSN: | 1897-4287 1731-2302 |
Popis: | Background Patients with DNA-damage response genes (DDR)-related pancreas cancer (BRCA1/2 or other DNA-damage related genes) may have improved outcomes secondary to increased sensitivity to DNA-damaging drugs (platinum chemotherapy/ poly ADP ribose polymerase (PARP)-inhibitors). However, data is scarce pertaining to outcomes in this subset of patients. Our objective was to retrospectively identify DDR-related pancreas cancer patients and report on clinical outcomes. Methods Pancreas cancer patients with a germline pathogenic variant in BRCA1/2 or other DDR gene were identified retrospectively through review of medical records (medical genetics/oncology) and genetic testing results at our institution. Data regarding clinical outcomes, therapy received, and survival was subsequently extracted. Results A total of 11 patients with pancreas cancer were identified to carry a pathogenic DDR-variant: BRCA1 (3), ATM (4), BRCA2 (2), PALB2 (1) and FANCC (1). Five of these individuals had prior history of other cancers. Clinically these tumors were localized (4), locally advanced (3), and metastatic (4) at diagnosis. Four out of 11 patients were still alive at time of data review. Survival in the 7 patients who had died was 13.7, 140.0, 20.5, 22.3, 23.5, 25.8, and 111.5 months. All patients with advanced disease had exposure to platinum chemotherapy. Conclusions Historical survival in patients with advanced and metastatic pancreas cancer is poor. Results of this DDR-subset of patients do show significantly superior outcomes, likely secondary to exposure to platinum drugs. This data, alongside other similar cohorts, would favor the DDR-genes being a predictive marker with improved survival if exposed to these drugs and the new class of drugs, PARP-inhibitors. |
Databáze: | OpenAIRE |
Externí odkaz: |